Sign in
4

Changes in Ownership

Karyopharm Therapeutics Inc. Filed Acc 0001209191-20-037229

Chief Executive Officer sold 7,500 shares at an average $16.37 ($122,779)

  • Chief Executive Officer acquired 7,500 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kauffman Michael · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2020-06-15 Exercise or conversion : show line 1 in the form +7,143 $0.03 $236 763,632 I
2020-06-15 Sale : show line 2 in the form −7,143 $16.38 $116,996 756,489 I
2020-06-15 Exercise or conversion : show line 3 in the form +357 $0.03 $12 756,846 I
2020-06-15 Sale : show line 4 in the form −357 $16.20 $5,783 756,489 I
Open-market sales · 7,500 sh · avg $16.37 · $122,779

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2020-06-15 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −7,143 $0.03 2020-10-31 7,143 16,424 I
2020-06-15 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −357 $0.03 2020-10-21 357 0 I
Loading xslF345X03/doc4.xml…